Rising Prevalence Of Psoriasis Patients Driving Market Growth Due To Increasing Demand For Advanced Biologic And Targeted Treatment Therapies Is Supporting Development Across The Psoriasis Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Psoriasis Market Over The Forecast Period?

The psoriasis market has demonstrated strong expansion in recent years. It is projected to increase from $28.93 billion in 2025 to $31.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The historical growth of this market can be ascribed to factors like the rising occurrence of autoimmune skin disorders, widespread application of corticosteroids, improved diagnosis rates in dermatology, the expansion of dermatology units in hospitals, and growing public awareness of chronic skin conditions.

The psoriasis market is projected to observe substantial expansion in the upcoming years. Its valuation is set to ascend to $44.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.3%. This projected growth is largely influenced by an increase in biologic drug approvals, heightened patient awareness, a rise in the diagnosis of severe psoriasis, the expansion of specialized clinics, and greater healthcare spending on dermatological care. Key developments expected during this period include the rising adoption of biologic treatments for psoriasis, the advancement of long-term disease management approaches, a growing demand for injectable psoriasis therapies, the broadening of hospital and specialty dermatology services, and an intensified focus on moderate-to-severe psoriasis cases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

Which Drivers Are Advancing The Psoriasis Market Growth?

An anticipated increase in the number of individuals affected by psoriasis is poised to stimulate the expansion of the psoriasis market in the future. This condition, psoriasis, is an enduring autoimmune skin ailment marked by accelerated skin cell accumulation, resulting in inflammation, flaking, and unease, frequently necessitating ongoing medical care and observation. The growing population of psoriasis sufferers stems from an immune system that erroneously targets healthy skin cells, a process often initiated or worsened by external elements like infections, psychological strain, or dermal injuries. This expanding prevalence of psoriasis bolsters the psoriasis market by generating higher demand for treatments such as biologics, topical preparations, immunomodulators, and light therapy options, all aimed at lessening outbreaks, alleviating signs, and improving the overall well-being of patients. As an illustration, in 2025, the Global Psoriasis Atlas, a UK-based research organization dedicated to psoriasis, estimated that 43 million individuals had psoriasis according to diagnoses from physicians and dermatologists, whereas around 102 million people self-reported having the condition. Consequently, the increasing incidence of psoriasis patients is fueling the development of the psoriasis market.

How Are Different Segment Groups Identified Within The Psoriasis Market?

The psoriasis market covered in this report is segmented –

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor

2) By Drug Types: Small molecules, Biologics

3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce

Subsegments:

1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)

2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)

3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

Which Trends Are Contributing To Changes In The Psoriasis Market?

Leading companies in the psoriasis market are prioritizing advancements in products and formulations, including autoinjector delivery systems for biosimilars. This focus aims to enhance patient adherence, convenience, and treatment outcomes, all while preserving the efficacy and safety profiles of their reference biologics. These technological solutions enable patients to self-administer medication, reduce injection discomfort, and foster wider acceptance of biosimilar therapies across Europe and other markets. For example, in May 2025, Sandoz, a biopharmaceutical company based in Switzerland, launched the Pyzchiva autoinjector, representing the first commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is designed to offer simple, accurate, and patient-friendly administration of biosimilar ustekinumab, which supports improved adherence for individuals managing chronic psoriasis. This launch underscores a market trend towards developing more patient-centric delivery options for biologics and biosimilars, thereby increasing accessibility and convenience for those living with psoriasis.

Which Key Players Are Active In The Psoriasis Market?

Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy

Access The Complete Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Which Area Represents The Largest Portion Of The Psoriasis Market?

North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Psoriasis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

Browse Through More Reports Similar to the Global Psoriasis Market 2026, By The Business Research Company

Psoriasis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Dermatology Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795